Caribou Biosciences (CRBU) investor relations material

Key insights from presentations

• Vispa-cel, an off-the-shelf allogeneic CAR T-cell therapy for large B-cell lymphoma, shows efficacy and safety on par with autologous CAR T, with potential for outpatient and community use.

• Clinical data from the ANTLER study highlight high response rates, durable remissions, and a manageable safety profile, especially with young donor T-cells and optimized HLA matching.

• The pivotal phase III trial will target second-line, transplant- and auto CAR T-ineligible patients, with endpoints including PFS, response, durability, OS, QoL, and safety.

• The panel emphasized the significant unmet need due to access barriers, with up to 60% of second-line patients being dual ineligible for current therapies.

• Community oncologists and academic leaders agree that off-the-shelf CAR T could transform access and outcomes, especially in underserved and rural populations.

Physician perspectives and real-world challenges

• Many eligible patients decline or cannot access CAR T due to travel, socioeconomic, or logistical barriers, with non-referral rates as high as 50-60% in some regions.

• Rapidly progressive disease and manufacturing delays often preclude timely autologous CAR T, making off-the-shelf options critical.

• Community centers are prepared to deliver intensive regimens and manage CAR T toxicities, especially with experience from bispecific programs.

• Academic centers also see value in allogeneic CAR T for patients with manufacturing failures, aggressive disease, or social/insurance constraints.

• Physicians anticipate that allogeneic CAR T will complement or even replace autologous products if efficacy and safety are maintained.

Forward-looking statements and future impact

• If approved, Vispa-cel could shift the treatment paradigm, enabling curative therapy in community settings and relieving academic center capacity.

• The therapy is expected to increase uptake in both community and academic centers, addressing the current gap where most eligible patients do not receive CAR T.

• Ideal product features include immediate availability, manageable safety, strong efficacy, and a platform for future enhancements.

• Expansion into other indications, including multiple myeloma and potentially solid tumors, is underway, with new data expected next year.

• The panel foresees a future where allogeneic CAR T is the standard, driven by scalability, logistics, and patient preference.